DK1492539T3 - Statin-terapi til forögelse af kognitiv funktion - Google Patents

Statin-terapi til forögelse af kognitiv funktion

Info

Publication number
DK1492539T3
DK1492539T3 DK03745196T DK03745196T DK1492539T3 DK 1492539 T3 DK1492539 T3 DK 1492539T3 DK 03745196 T DK03745196 T DK 03745196T DK 03745196 T DK03745196 T DK 03745196T DK 1492539 T3 DK1492539 T3 DK 1492539T3
Authority
DK
Denmark
Prior art keywords
cognitive function
statin
statin therapy
enhance cognitive
galantamine
Prior art date
Application number
DK03745196T
Other languages
English (en)
Inventor
Sean Lilienfeld
Elane M Gutterman
Royston John Glasspool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1492539T3 publication Critical patent/DK1492539T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK03745196T 2002-04-02 2003-03-28 Statin-terapi til forögelse af kognitiv funktion DK1492539T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02

Publications (1)

Publication Number Publication Date
DK1492539T3 true DK1492539T3 (da) 2006-10-30

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03745196T DK1492539T3 (da) 2002-04-02 2003-03-28 Statin-terapi til forögelse af kognitiv funktion

Country Status (22)

Country Link
EP (1) EP1492539B1 (da)
JP (1) JP2005525391A (da)
KR (1) KR100986194B1 (da)
CN (1) CN100528164C (da)
AT (1) ATE331523T1 (da)
AU (1) AU2003226753B2 (da)
BR (1) BR0308293A (da)
CA (1) CA2480275C (da)
CY (1) CY1105545T1 (da)
DE (1) DE60306503T2 (da)
DK (1) DK1492539T3 (da)
EA (1) EA013069B1 (da)
ES (1) ES2268393T3 (da)
HK (1) HK1079688A1 (da)
IL (2) IL164317A0 (da)
MX (1) MXPA04009535A (da)
NO (1) NO20044698L (da)
NZ (1) NZ536111A (da)
PL (1) PL211160B1 (da)
PT (1) PT1492539E (da)
UA (1) UA79605C2 (da)
WO (1) WO2003082298A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
JP2007532624A (ja) * 2004-04-14 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルツハイマー病の治療のための療法組合せ
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Also Published As

Publication number Publication date
PT1492539E (pt) 2006-11-30
CN1642555A (zh) 2005-07-20
EA013069B1 (ru) 2010-02-26
HK1079688A1 (en) 2006-04-13
CA2480275C (en) 2011-08-16
AU2003226753B2 (en) 2007-06-28
DE60306503T2 (de) 2007-06-21
JP2005525391A (ja) 2005-08-25
ES2268393T3 (es) 2007-03-16
NZ536111A (en) 2006-03-31
PL211160B1 (pl) 2012-04-30
IL164317A0 (en) 2005-12-18
WO2003082298A1 (en) 2003-10-09
KR100986194B1 (ko) 2010-10-07
CA2480275A1 (en) 2003-10-09
BR0308293A (pt) 2004-12-28
CN100528164C (zh) 2009-08-19
AU2003226753A1 (en) 2003-10-13
EP1492539B1 (en) 2006-06-28
MXPA04009535A (es) 2005-01-25
EP1492539A1 (en) 2005-01-05
CY1105545T1 (el) 2010-07-28
DE60306503D1 (de) 2006-08-10
KR20040096608A (ko) 2004-11-16
EA200401295A1 (ru) 2005-02-24
PL371551A1 (en) 2005-06-27
ATE331523T1 (de) 2006-07-15
IL164317A (en) 2010-04-29
UA79605C2 (en) 2007-07-10
NO20044698L (no) 2004-10-29

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
BG105342A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
HUP0300043A2 (en) Method and composition for the treatment of pain
DE60122764D1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa